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Current methods for nasal spray formulations have been elementary evaluating the dripping char-
acteristics of a formulation and have not assessed the behavior of the nasal formulation in the presence
of varying types of mucus depending on the indication or diseased state. This research investigated the
effects of nasal mucus on the dripping behavior of nasal formulations and focused on developing an
improved in vitro analytical test method that is more physiologically relevant in characterizing nasal
formulation dripping behavior. Method development was performed using simulated nasal mucus
preparations for both healthy and diseased states as coatings for the dripping experiment representing a
wide range of viscosity. Factors evaluated during development of this in vitro test method included
amount of mucus, application of mucus, drying times, and compatibility of the mucus on a C18 Thin Layer
Chromatography (TLC) substrate. The dripping behavior of nasal formulations containing a range of 1%
Avicel to 3.5% Avicel was assessed by actuating the nasal spray on a perpendicular TLC plate coated with
either healthy or diseased simulated nasal mucus. After actuation of the nasal spray, the dripping of the
formulation on the coated TLC plate was measured after the plate was repositioned vertically. The
method that was developed generated reproducible results on the dripping behavior of nasal formula-
tions and provided critical information about the compatibility of the formulation with the nasal mucus
for different diseased states, aiding in nasal spray formulation development and physical characterization
of the nasal spray.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Physiologically, the nasal mucosa naturally produces an abun-
dance of nasal mucus when in a healthy state for purposes of pro-
tecting the nasal mucosa from drying out and trapping unwanted
substances. Excessive nasal mucus may be secreted by patients suf-
fering from allergic rhinitis, sinusitis and the common cold. Nasal
mucus roughly consists of 95% water, 2.5% glycoproteins, 1%–2%
electrolytes and other still incompletely deﬁned components among
which are lysozyme, lactoferrin, complement, and possible liquid
fractions similar to surfactant [1–3]. The qualitative and quantitative
features of the glycoproteins are primarily responsible for the rheo-
logical properties of the nasal secretions [4–6]. Important rheological
features of mucus include viscosity, elasticity, adhesiveness, and the
ability to be spun (“spinability”) and poured (“pourability”) [7].
Nasal spray is a unique drug delivery means that has been
widely used to deliver medication to the intranasal cavity to treaton and hosting by Elsevier B.V. Th
University.
k).numerous topical diseases such as allergic rhinitis, sinusitis, and
nasal congestion for those suffering from the common cold. Other
emerging applications of nasal sprays include vaccination delivery
and the treatment for migraine via intranasal delivery. Formula-
tion adherence to mucosa (e.g. residence effectiveness in the nasal
cavity) and patient comfort are important factors often considered
during nasal spray formulation development. A non-dripping form
of a nasal spray formulation has been developed usually contain-
ing thixotropic agents such as microcrystalline cellulose to achieve
the desired viscosity proﬁle resulting in lower viscosity when
shear stress is applied and increasing viscosity in its absence.
Analytical methods assessing the dripping behavior of nasal spray
formulations have not been commonly used for formulation de-
velopment. A simple invitro method of employing a paper sheet as
the spray substrate has been developed to assess the dripping
behavior of nasal spray formulations and is also used to guide
formulation development. However, this method hardly predicts
or correlates with how the nasal spray formulation behaves inside
the nasal cavity. Perhaps besides anatomical structure of the hu-
man nose, the most signiﬁcant factor that should be considered is
the interaction of the formulation with nasal mucus. Furthermore,
mucus characteristics vary depending on the type and stage ofis is an open access article under the CC BY-NC-ND license
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those exhibiting allergic rhinitis, to thick and viscous for a patient
suffering from chronic sinusitis [8,9]. Current methods in the la-
boratory evaluating the nasal dripping characteristics of a for-
mulation are elementary and do not assess the behavior of the
nasal formulation in the presence of varying types of mucus de-
pending on the indication or diseased state.
Therefore, the goal of this research was to investigate the ef-
fects of nasal mucus on the dripping behavior and physical prop-
erties of nasal formulations, and to develop an improved invitro
analytical test method that is more physiologically relevant in
characterizing nasal formulation dripping behavior generating
reproducible results. The ultimate objective was to support
formulation development by formulating a nasal spray for
compatibility with the nasal mucus associated with a particular
diseased state or indication for which the nasal spray is intended.
To evaluate the interaction of formulation and nasal mucus,
healthy simulated nasal mucus and diseased simulated nasal
mucus were selected as coatings for the development of an ana-
lytical dripping method.Fig. 1. Nasal spray apparatus.2. Experimental
2.1. Materials
Various types of dyes including allura red AC, methylene blue,
alcian blue GX, congo red and crystal violet were purchased from
Sigma-Aldrich (St. Louis, Missouri, USA). Nano Silica TLC plates,
Cellulose Plastic TLC plates, and Cellulose Aluminum TLC plates
were all sourced from Sigma-Aldrich (St. Louis, Missouri, USA). The
microcrystalline cellulose (Avicel) was sourced internally from
Merck MSD (Rahway, New Jersey, USA).
For the preparation of healthy simulated nasal mucus, porcine
mucin type II, sodium chloride, and potassium chloride were all
sourced from Sigma-Aldrich (St. Louis, Missouri, USA) and the
calcium chloride dihydrate was sourced from Fisher Scientiﬁc (Fair
Lawn, New Jersey, USA).
For diseased simulated nasal mucus, locust bean gum (LBG),
saline solution, and sodium dodecyl sulfate (SDS) were sourced
from Sigma-Aldrich (St. Louis, Missouri, USA), Bio-world (Dublin,
Ohio, USA), and Invitrogen (Carlsbad, California, USA), respectively.
2.2. Instrument and characterization
A stainless steel actuation apparatus for nasal sprays was de-
signed by Merck Engineering for this dripping study (Fig. 1). The
apparatus was designed to seat a nasal spray device with the
ability for manual actuation, taking into account stroke length for
the nasal spray bottle. It also had a metal plate with an afﬁxed TLC
plate that can be positioned perpendicular to the nasal spray
bottle during actuation and then repositioned 90 degrees verti-
cally after actuation for evaluation of dripping behavior. The dis-
tance between the nasal spray tip and this metal plate was set at
3 cm. A digital camera was placed horizontally across from the
stainless steel apparatus at a ﬁxed distance and used to record the
nasal formulation dripping time-elapse proﬁle.
In addition, characterization of the simulated nasal mucus was
performed by testing viscosity and surface tension. The surface
tension was evaluated on a Kruss DSA-3 Surface Tension Analyzer
in pendant drop mode (single drop measurement). The viscosity of
each of the coatings and formulations were determined on a
Brookﬁeld Viscometer DV-II Pro. A 5 mL sample was transferred
into the sample cup and equilibrated for 30 min in an undisturbed
water bath at 37 °C. Rotations at 100 rpm were started after the
30 min and measurements were recorded at 0, 5 and 10 min. ASpraytecs laser diffraction system (Malvern Instrument Ltd.,
Westborough, MA) measured the droplet size distribution of the
nasal sprays. The SprayView NSP system equipped with a high-
speed camera (Proveris Scientiﬁc Corp., Westborough, MA) mea-
sured spray pattern of the nasal sprays.
2.3. Nasal formulation preparation
Six placebo formulations were prepared for this study con-
taining varying amounts of Avicel (1%, 1.5%, 2%, 2.5%, 3% and 3.5%
(m/m)). A stock solution was made by gradually charging 40 g of
Avicel to 800 g of water in a steel compounding vessel (tempera-
ture 2575 °C) and continuously mixed at 350 rpm while re-
circulating through an in-line homogenizer (IKA Ultra Turrax T25)
at a ﬂow rate of 1 L/min for 30 min. After 30 min, 200 g of water
was added to the compounding vessel and continued mixing for
another 10 min. Variable amounts of stock solution and water
were combined to achieve each of the desired concentrations of
Avicel. Dye was added to each formulation at a concentration of
0.05% (m/m) followed by agitation once more at 350 rpm for
10 min. The ﬁnal formulation was ﬁlled into a nasal spray bottle
with a spray pump to deliver 100 mL per actuation.
2.4. Simulated mucus preparation and coating
Healthy nasal mucus was simulated by preparing a solution of
porcine mucin in buffer exhibiting properties such as watery and
non-viscous [10]. Conversely, a type of mucus that may exemplify
a diseased state such as chronic sinusitis displaying highly viscous
properties was simulated by a preparation of LBG and SDS in saline
solution [11]. The healthy simulated nasal mucus was prepared by
adding porcine mucin type II to a buffer solution consisting of
7.5 mg/mL of sodium chloride, 1.3 mg/mL of potassium chloride,
and 0.3 mg/mL of calcium chloride dihydrate to attain an overall
concentration of porcine mucin of 8% (m/m) in buffer. The dis-
eased simulated nasal mucus was prepared by heating a beaker
containing 100 mL of saline solution and SDS at a concentration of
6 mM to 80 °C. Once the solution reached a temperature higher
than 70 °C, the LBG was slowly added while mixing until a ﬁnal
temperature of 80 °C was attained and the LBG was dissolved.
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and mixed in to achieve mass balance from losses during heating,
mixing and evaporation. This preparation of mucus has similar
physical properties to real human diseased mucus exhibiting high
viscosity due to the high concentration of LBG.
2.5. Method development for coating application
Multiple experiments were performed to develop a method to
assess the dripping behavior of the nasal spray formulations with
simulated nasal mucus coated on a TLC plate as a substrate. TLC
plates (10 cm10 cm) were selected because various types of
coatings (i.e. different chemistry) were available on the plates with
porous and hydrophilic characteristics compatible with the simu-
lated human mucus. Different types of TLC plates were evaluated
during the coating experiments to determine which was most
compatible with the simulated human mucus displaying a uniform
coating without beading on the plate. In addition, the plates were
the ideal size to ﬁt in the nasal spray apparatus and large enough to
capture the dripping experiment over 30 s. Further experiments
were performed to optimize the volume and application technique
of the nasal mucus for development of a repeatable and re-
producible method. In order to achieve this, the key parameter of
non-dripping was assessed to assure that the simulated mucus
when applied to the TLC plate did not drip when positioned hor-
izontally (upside down) during nasal spray actuation and vertically
at a 90° angle during the dripping analysis part of the experiment. A
visual check of the simulated nasal mucus after application to the
TLC plate was also evaluated to ensure that it did not dry. Therefore,
application experiments for the simulated mucus focused on de-
termining a ﬁnal method which was bracketed by a lower and upper
range in terms of volume and drying time (if necessary) that would
still produce no dripping of the applied simulated mucus during the
test. The application method, such as brushing technique during
distribution of the simulated mucus, was also evaluated to ensure
control and consistency. Once the parameters were optimized, they
were assessed by testing replicates (n¼2) for the 1% Avicel and 3.5%
Avicel formulations, bracketing the complete range of Avicel in the
formulations. The replicates for each of the formulations were very
comparable when assessed for dripping behavior at 5, 10, 15, 20, 25
and 30 s. Both of the methods assessing the healthy simulated
mucus with porcine mucin in buffer and the diseased simulated
mucus with LBG were developed with this approach, achieving the
goal of analyzing the dripping behavior of nasal spray formulations
in a robust and reproducible way.
For the healthy simulated nasal mucus with buffer method,
1.0 mL of solution was applied to the cellulose side of a cellulose
plastic TLC plate (10 cm10 cm). Droplets of the mucus were
applied evenly on the periphery and the interior of the TLC plate to
allow for even dispersion. The mucus was then distributed with a
paintbrush for even application covering the entire TLC plate and
air dried for 1 min prior to the dripping analysis.
The method for dripping analysis with the diseased simulated
mucus with LBG as a coating, entailed adding 2 g of mucus to the
cellulose side of a cellulose aluminum TLC plate (10 cm10 cm). A
1 inch brush was utilized to evenly distribute the diseased nasal
mucus. A net weight of 1.5 g was targeted after brushing in a
uniform pattern (up/down) covering the entire TLC plate. The
dripping analysis occurred immediately after the ﬁnal step of ap-
plication of the mucus with no drying time.
2.6. Dripping assessment method
The dripping assessment method was performed on each of the
formulations listed in Section 2.3 containing a range of 1%–3.5%
Avicel. In addition, two commercial formulations designated“commercial A no drip” and “commercial B” were included in the
study. Once simulated nasal mucus was applied to a TLC plate
(10 cm10 cm) and dried, if necessary, the TLC plate was afﬁxed
to the nasal dripping study apparatus. A primed nasal spray bottle
containing formulation was then shaken in a horizontal plane for
10 s prior to placement in the nasal bottle seating and was im-
mediately actuated vertically. Once actuated, the metal plate
holding the horizontal TLC plate was moved in a 90° vertical di-
rection and the dripping distance was measured at 0, 5, 10, 15, 20,
25, and 30 s while the camera simultaneously captured images of
the formulation dripping at these times. If the formulation dripped
off the TLC plate, no further data was collected for that particular
replicate. Duplicate replicates (n¼2) were performed for each
formulation and the dripping distances (mm) were averaged for
each time point. In addition to dripping distance, the dripping
speed (mm/s) was also calculated for further analysis about the
dripping behavior of the formulations.3. Results and discussion
3.1. Selection of dye and characterization experiments
Dye was added to the nasal formulation during its preparation
to aid in visualization of the dripping process. Several dyes were
evaluated including allura red AC, methylene blue, alcian blue GX,
congo red and crystal violet. Dyes were assessed and selected
based on having a high absorptivity and good solubility in water.
Preliminary experiments showed the crystal violet dye exhibited
intense color when added to the formulations even at a relatively
low concentration of 0.05% (m/m). Further testing conducted
conﬁrmed that the addition of crystal violet dye did not cause any
signiﬁcant changes in physical properties to the formulations.
Viscosity, spray pattern and droplet size testing were all per-
formed to compare the formulation with dye and without. A direct
comparison of a formulation with dye and without showed no
practical signiﬁcant difference in viscosity (r5%). In addition,
droplet size distribution data (Dv10, Dv50, Dv90, and span) and
spray pattern data such as minimum spray diameter (Dmin),
maximum spray diameter (Dmax), ovality, and % area (Fig. 2)
further conﬁrmed that there was no signiﬁcant impact of adding
crystal violet dye with respect to affecting the physical char-
acteristics of the formulation which would ultimately affect the
dripping behavior of the nasal spray. Therefore, for purposes of
visualizing dripping behavior, crystal violet dye was selected to
add into all nasal spray formulations. Six placebo formulations
with 0.05% (m/m) crystal violet dye were prepared for this study
containing increasing amounts of Avicel including 1%, 1.5%, 2%,
2.5%, 3% and 3.5% (m/m). It should be noted that there was an error
during the preparation of the 2.5% Avicel formulation which was
not included in the subsequent nasal dripping experiments.
The droplet size data (Dv10, Dv50, and Dv90) appear to de-
monstrate a general trend of an increase in larger droplets during
actuation as the % Avicel in the formulation is increased irre-
spective of the addition of dye. There is also an apparent shift to
higher span values conﬁrming the effect that higher concentra-
tions of Avicel have on droplet size distribution. A comparison of
the placebo formulation and the placebo with dye formulation
shows no signiﬁcant differences in droplet size distribution, sug-
gesting that the dye has no impact on the physical properties of
the formulation. Therefore, the droplet size data support that
adding the dye for purposes of assessing the dripping behavior for
this nasal spray formulation is acceptable.
An evaluation of the spray pattern data suggests that the ad-
dition of dye to the placebo formulation does not affect the spray
pattern attributes since the data is comparable between the
Fig. 2. Nasal spray formulation characterization data: (A) droplet size distribution, (B) span, (C) Dmin and Dmax, (D) Ovality, and (E) Area %.
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ality and area %. However, the spray pattern data with respect to
increasing the % Avicel in the nasal spray formulations appears to
be somewhat inconclusive with no obvious trend for ovality, Dmin
and Dmax while exhibiting a trend of decreasing spray pattern
area %. This may be attributed to the increased viscosity of the
formulation as the % Avicel is increased.
3.2. Selection of coatings and ﬁnalized coating technique methods
Different coatings and coating techniques were assessed for the
nasal dripping experiment. Simulated mucus representing healthy
mucus with a watery, thin consistency and diseased mucus similar
to very viscous, thick mucus commonly associated with chronic
sinusitis were selected to investigate the interaction and dripping
properties of mucus with formulation containing various amounts
of Avicel ranging from 1% to 3.5%. As stated earlier, viscosity is an
important characteristic of nasal mucus and therefore, the two
simulated mucus types were a good option to bracket the full
range of all types of nasal mucus. Low viscosity was associated
with healthy mucus and a very high viscosity was typical for the
diseased mucus with values of 13 cP and 1400 cP, respectively.
Both types of simulated mucus had similar values in surface ten-
sion (approximately 30 mN/m). The property of surface tension is
also important for nasal mucus because it is related toadhesiveness, another characteristic of nasal mucus, and may
provide some critical information about the interaction of the si-
mulated nasal mucus and formulation. The coating substances
selected for this experiment were a healthy simulated nasal mucus
made with porcine mucin in buffer and a diseased simulated nasal
mucus comprised of LBG and SDS in saline solution. For the ex-
periment assessing nasal dripping on paper, no coating was ap-
plied. The ﬁnal method evaluating healthy simulated nasal mucus
involved applying 1.0 mL of mucus to the cellulose side of a cel-
lulose plastic TLC plate, evenly distributing droplets on the per-
iphery and interior of the TLC plate to allow for even dispersion.
The healthy mucus was dried for 1 min prior to analysis. The ﬁnal
method assessing diseased simulated nasal mucus involved adding
2 g of mucus to the cellulose side of a cellulose aluminum TLC
plate and evenly distributing a target net weight of 1.5 g after
brushing in a uniform pattern. Both of the coating methods de-
scribed for simulated nasal mucus resulted in robust methods
generating reproducible results.
Further characterization was performed on the coatings by
testing viscosity, surface tension and density. The viscosity data
generated for the diseased simulated mucus with LBG conﬁrms
that it is very viscous (1400 cP) and is representative of a dis-
eased state such as chronic sinusitis in which the mucus is de-
scribed as thick and viscous as determined by Majima, et al. [9].
Conversely, the viscosity of the healthy mucus is low (13 cP)
Fig. 3. Formulation dripping distance vs. time with (A) no coating on paper, (B)
healthy simulated nasal mucus and (C) diseased simulated nasal mucus.
Table 1.
Average dripping speed of formulation with simulated mucus at different time
points.
Mucus Formulation Average dripping speed (mm/s)
0 5 10 15 20 25 30
Commercial A
no drip
0 0.4 – – – – –None (Paper)
Commercial B 0 8.0 6.4 4.7 – – –
Placebo 0 2.6 5.0 4.3 3.4 – –
Avicel 1% 0 12.2 – – – – –
Avicel 1.5% 0 9.8 6.5 – – – –
Avicel 2% 0 3.5 3.1 3.3 2.6 2.6 –
Avicel 3% 0 1.1 1.5 1.7 1.7 1.5 1.4
Avicel 3.5% 0 1.1 0.9 0.8 0.8 0.7 1.7
Healthy simu-
lated mucus
Commercial A
no drip
0 0.4 0.3 – – – –
Commercial B 0 6.8 4.7 3.7 3.0 2.5 2.2
Placebo 0 3.8 2.4 1.8 1.5 1.2 1.1
Avicel 1% 0 6.2 5.0 3.9 – – –
Avicel 1.5% 0 4.7 3.3 2.8 2.5 2.2 –
Avicel 2% 0 1.0 1.1 1.0 0.9 0.9 0.9
Avicel 3% 0 0.5 0.5 0.5 0.5 0.5 0.5
Avicel 3.5% 0 0.3 0.3 0.2 0.2 0.2 0.2
Diseased si-
mulated
mucus
Commercial A
no drip
0 0.6 – – – – –
Commercial B 0 13.4 – – – – –
Placebo 0 12.6 – – – – –
Avicel 1% 0 12.2 – – – – –
Avicel 1.5% 0 13.2 – – – – –
Avicel 2% 0 9.9 5.6 3.7 2.8 2.3 1.9
Avicel 3% 0 4.6 2.5 1.7 1.4 1.1 1.0
Avicel 3.5% 0 1.0 0.9 0.7 0.6 0.5 0.5
“–” indicates no measurement calculated since formulation dripped off the
substrate.
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cavity of healthy individuals [12]. The two types of mucus exhibit
two extremes in terms of nasal mucus with respect to viscosity
and encompass a wide range of viscosity values for different types
of mucus.
The surface tension data of approximately 30 mN/m for both
the healthy simulated nasal mucus and the diseased nasal mucus
demonstrate that both have a relatively low surface tension. Fur-
ther, the surface tension values are critical because it provides
information on how well the simulated mucus will disperse when
applied to the TLC substrate. During the experiment, both the
healthy and diseased simulated nasal mucus dispersed with ease
across the TLC plate with no beading. The density of the healthy
and diseased simulated nasal mucus was also tested for informa-
tional purposes and yielded a density of approximately 1.00 g/mL
and 0.94 g/mL, respectively.
3.3. Dripping study
The dripping behavior of ﬁve formulations of 1%, 1.5%, 2%, 3%,
3.5% Avicel and two commercial formulations (commercial A no
drip and commercial B) were evaluated when applied to TLC plates
with coatings representing simulated nasal mucus for a healthy
and diseased individual. In addition, the dripping behavior of the
formulations was also assessed on paper with no coating to serve
as a control for the experiment.
The results comparing the formulation dripping behavior on
paper with no coating demonstrated a trend in which increasing
Fig. 4. Dripping distance vs. time for (A) commercial A no drip, (B) commercial B, (C) 1%, (D) 1.5%, (E) 2%, (F) 3%, and (G) 3.5% Avicel formulations with different coatings.
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(Fig. 3A). Formulations with 1.5% Avicel or less will drip off the
paper in about 10 s. The commercial A no drip formulation ex-
hibited a true no drip proﬁle by traveling less than 5 mm during
the 30 s test. The paper method, however, does not provide anyinformation on how the formulation will interact with nasal mu-
cus and may only be useful in comparing different formulations
during formulation development to assess dripping behavior. In
addition, paper is porous and may absorb some of the formulation
when actuated. The presence of mucus may result in more
Fig. 5. Images of (A) 1%, (B) 1.5%, (C) 2%, (D) 3%, and (E) 3.5% Avicel formulations at 30 s after actuation on a TLC plate coated with healthy simulated mucus.
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properties of each when interacting. This test may not always
correlate with how the nasal spray will perform in vivo. For ex-
ample, nasal anatomy, nasal temperature and nasal humidity can
also have signiﬁcant effects. It is possible that some nasal for-
mulations may exhibit a completely different dripping proﬁle
when actuated into a human nose. However, with the addition of
simulated nasal mucus to a TLC substrate, depending on the in-
dication that is targeted, it may provide relevant information for
formulation development by comparing varying amounts of Avicel
in the formulation by qualitative analysis. It is also a critical ana-
lytical test that performs physical characterization of a nasal
formulation.
For the experiment assessing dripping distance when applied
to a healthy mucus coating, there appears to be a trend in which
increasing the % Avicel in the formulation correlates to the total
dripping distance decreasing through 30 s indicating a slower
dripping rate (Fig. 3B). It also indicates that formulations with an
increased Avicel content also demonstrate dripping behavior that
is more linear and then levels off to a non-dripping state once the
Avicel level is greater than or equal to 3%. The healthy mucus made
with porcine mucin and buffer salts diluted in a buffer solution
reﬂects that of a healthy individual and also is similar to mucus
produced by those with allergic rhinitis and is watery and has low
viscosity in nature. Therefore, this experiment may prove to be
useful in assessing formulations for allergic rhinitis and also newer
indications in which diseased viscous mucus is not a factor. De-
livery of drug by a nasal spray with the potential for the drug to
cross the blood brain barrier may be assessed for much newer
indications in which nasal sprays historically have not been a
dosage form. Therefore, there is potential in using this method forevaluating the dripping behavior of these types of formulations
which may contain different excipients contributing to different
dripping proﬁles.
The LBG coating representing diseased mucus appears to show
a trend that as the % Avicel is increased in the formulation, the less
probable it is to drip as measured by a shorter dripping distance
after actuation (Fig. 3C). In addition, the majority of dripping oc-
curs within the ﬁrst 5–10 s after actuation as indicated by a steeper
slope and then tends to stabilize afterwards through the 30 s of
measurement. The formulations containing less than 2% Avicel
display immediate dripping off the TLC substrate coated with
mucus whereas the formulations containing greater percentages
of Avicel demonstrate a slower, almost constant dripping rate after
the initial 5 s. This data supports that the formulation has an af-
ﬁnity for the LBG mucus from a diseased state when increased
levels of Avicel are present, indicating that it would not repel the
formulation. Furthermore, it suggests that the residence time of
the formulation may be increased in the nose since there is much
less dripping especially with formulations containing higher per-
centages of Avicel.
The average dripping speeds of all formulations were also cal-
culated when analyzed with both types of mucus and without. In
all three experiments, there is an obvious trend that as the % Avicel
increases in the formulation, the dripping speed decreases. The
formulations also tend to show a relatively constant or decrease in
speed when evaluated over time for all 3 experiments. Table 1
displays the results for the calculated average dripping speeds for
all formulations in the presence of mucus and without. The drip-
ping speed is much slower for the Avicel formulations when
analyzed on a TLC plate coated with healthy simulated mucus
when compared to the results for diseased simulated mucus and
Fig. 6. Images of (A) 1%, (B) 1.5%, (C) 2%, (D) 3%, and (E) 3.5% Avicel formulations at 30 s after actuation on a TLC plate coated with diseased simulated mucus.
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have more similar properties to the healthy simulated mucus and
therefore, have less of a tendency to drip. Conversely, the for-
mulations, ranging in viscosity from 80 to 500 cP may be less si-
milar to the highly viscous diseased simulated mucus (about
1400 cP), possibly resulting in a faster dripping rate.
The dripping behavior of each formulation (distance vs. time)
was also individually analyzed and compared to the healthy and
diseased simulated mucus and paper (no mucus) methods (Fig. 4).
Images were captured for each of the formulations at 30 s after
actuation on a TLC plate coated with the healthy simulated nasal
mucus (Fig. 5) and diseased simulated nasal mucus (Fig. 6),
respectively.
All ﬁgures for the 1%–3.5% Avicel formulations demonstrate a
trend of decreased dripping as the % Avicel increases in the for-
mulation when analyzed on a TLC plate with healthy and diseased
simulated mucus and paper with no coating. The commercial A no
drip formulation appears to exhibit a true no drip proﬁle (Fig. 4A).
The healthy simulated mucus appears to have the least dripping
distance for all of the formulations.
The diseased simulated mucus and paper no coating methods
appear to generate more similar results with increased dripping
distances. Interestingly, the nasal spray formulations containing
lower % Avicel (1%–2%) show increased dripping for the diseased
simulated nasal mucus when compared to the paper method with
no coating. However, this relationship changes when the % Avicel
is increased in the formulation to 3%–3.5% with less dripping oc-
curring for the diseased simulated mucus method. The increase in
viscosity of the formulations becoming more similar to the highly
viscous diseased simulated mucus may be the reason for this
change.4. Conclusion
The tendency to drip when a formulation is actuated onto a
coated surface may provide useful information about how effec-
tive or efﬁcacious a formulation might be when used for a certain
diseased state. Even though the complex anatomy of the nasal
cavity is not investigated in this study, the compatibility of a for-
mulation with the nasal mucus on a TLC plate provides critical
information about the interaction between the two. This is im-
portant because of the abundance of nasal mucus that exists in the
nasal cavity regardless of an individual in a healthy state or af-
ﬂicted with chronic sinusitis, allergic rhinitis or the common cold.
Furthermore, a formulation that has very different characteristics
from a particular nasal mucus may have more of a tendency to
drip or, in human subjects, drip out of the nose with less residence
time, so no therapeutic beneﬁt is achieved.
From a formulation and patient use perspective, the % Avicel
added to a nasal formulation is critical because it may affect pa-
tient comfort when administering the nasal spray to the nasal
cavity. Higher percentages of Avicel added to a formulation can
decrease the overall size of the spray pattern (with a narrower
plume), resulting in a much more bullet-like effect actuating into
the posterior nasal cavity correlating to higher patient discomfort.
This is most likely related to the increased viscosity of the for-
mulation [13]. Conversely, lower % Avicel formulations have a
larger spray pattern (with wider plume) from the lower viscosity
of the formulation and may deposit in the more anterior region of
the nose with the undesirable effect of dripping out of the nose.
Therefore, there is a balance that must be achieved when for-
mulating nasal sprays and how the formulation will interact in the
presence of various types of nasal mucus associated with different
T. Masiuk et al. / Journal of Pharmaceutical Analysis 6 (2016) 283–291 291indications may need to be investigated during formulation de-
velopment. By developing an in vitro test method using various
coatings to simulate nasal mucus, there is more biorelevance in
characterizing the dripping behavior of nasal spray formulations
which further supports formulation development and may pro-
vide more information about nasal spray deposition.
The development of a method evaluating the dripping behavior
of a nasal spray formulation is important for characterization
during formulation development. By assessing the dripping be-
havior in the presence of simulated nasal mucus, there is increased
knowledge and understanding of the developed formulation by
the differentiating factor with the addition of the nasal mucus.
Furthermore, with nasal sprays being developed for new indica-
tions, different excipients may be employed requiring greater
understanding of the formulation interaction with nasal mucus.
Therefore, it is useful in developing a nasal spray dripping method
which aids in formulation development and provides critical in-
formation about the compatibility of the formulation with nasal
mucus, resulting in a method more physiologically relevant than a
paper-based dripping method.Acknowledgments
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